Ardent Capital Management Inc. Has $1.31 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ardent Capital Management Inc. cut its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,443 shares of the medical equipment provider’s stock after selling 182 shares during the period. Zimmer Biomet accounts for about 0.6% of Ardent Capital Management Inc.’s investment portfolio, making the stock its 15th biggest holding. Ardent Capital Management Inc.’s holdings in Zimmer Biomet were worth $1,314,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ZBH. Blue Trust Inc. boosted its position in Zimmer Biomet by 165.3% during the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock valued at $187,000 after purchasing an additional 1,071 shares during the last quarter. Eastern Bank acquired a new position in Zimmer Biomet during the third quarter valued at approximately $382,000. BLB&B Advisors LLC boosted its position in Zimmer Biomet by 2.1% during the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after purchasing an additional 100 shares during the last quarter. Courier Capital LLC boosted its position in Zimmer Biomet by 46.1% during the third quarter. Courier Capital LLC now owns 6,054 shares of the medical equipment provider’s stock valued at $654,000 after purchasing an additional 1,910 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its position in Zimmer Biomet by 19,988.0% during the third quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock valued at $11,601,000 after purchasing an additional 106,936 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $103.64 on Friday. The firm has a market cap of $20.63 billion, a P/E ratio of 23.29, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1-year low of $97.69 and a 1-year high of $133.90. The business’s 50 day moving average is $105.90 and its 200-day moving average is $107.48.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.93%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analysts Forecast Growth

ZBH has been the subject of several recent research reports. Barclays reduced their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Wells Fargo & Company upped their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Royal Bank of Canada dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Raymond James dropped their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.